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ABSTRACT: 
 
Objective: To undertake a comprehensive assessment of the strength of preferences among 
young people for attributes of emerging technologies for testing and treatment of 
asymptomatic chlamydia. 
 
Design: Discrete choice experiment (DCE) with sequential mixed methods design. A staged 
approach to selection of attributes/ levels included two literature reviews, focus groups with 
young people aged 16-24 years (n = 21), experts’ review (n=13), and narrative synthesis. 
Cognitive testing was undertaken to pilot and adapt the initial questionnaire. Online national 
panel was used for final DCE survey to maximise generalisability. Analysis of questionnaire 
responses used multinomial logit models and included validity checks.  
 
Setting: England. 
 
Participants: 1,230 young people aged 16-24 from a national online panel (completion rate 
73%). 
 
Outcome Measures: Odds Ratios (ORs) for service attributes in relation to reference levels. 
 
Results: The strongest attribute influencing preferences was chlamydia test accuracy (OR 
3.24, 95% CI 3.13–3.36), followed by time to result (OR 1.81, 95% CI 1.71–1.91). Respondents 
showed a preference for remote chlamydia testing options (self-testing, self-sampling and 
postal testing) over attendance at a testing location. For accessing treatment following a 
positive test result, there was a general preference for online (OR 1.21, 95% CI 1.15–1.28) 
versus traditional GP (OR 1.18, 95% CI 1.12–1.24) or pharmacy (OR 1.15, 95% CI 1.10–1.22) 
over clinic services.  For accessing a healthcare professional and receipt of antibiotics, there 
was little difference in preferences between options.  
 
Conclusions: 
Both test accuracy and very short intervals between testing and results were important 
factors for young people when deciding whether to undergo a routine test for asymptomatic 
chlamydia, with test accuracy being more important. These findings should assist technology 
developers, policy makers, commissioners and service providers to optimise technology 
adoption in service redesign, although use of an online panel may limit generalisability of 
findings to other populations. 
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Strengths and Limitations of the Study: 
 
 To our knowledge, this is the first large-scale DCE study to examine the preferences 
of a geographically representative national sample of young people for emerging 
technologies designed to improve screening for and treatment of asymptomatic 
chlamydia. 
 Robust sequential methods were used to select final DCE attributes and levels, 
including two literature reviews, focus groups with young people, and review by 
expert groups. 
 An online panel enabled access to the population targeted for screening, including 
young people with no personal experience of chlamydia testing and treatment. 
 Limitation of this work included: (i) the literature reviews inevitably identified more 
potential attributes than could be included in the DCE; (ii) information was 
unavailable on those who opened but did not agree to complete the questionnaire 
so systematic comparison with responders was not possible. 
 The use of an online panel may limit generalisability of findings to the 97% of 15-24 
year-olds who currently access the internet daily, and therefore over-represent the 
acceptability of online care to some. 
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 1 
INTRODUCTION: 2 
Chlamydia is the most commonly reported sexually transmitted infection (STI) in England, 3 
with young people aged 15-24 accounting for 63% of diagnoses in 2016.1  The estimated 4 
annual cost of chlamydia treatment in 2015 was £249.8 million.2  Undetected infections and 5 
re-infections can lead to significant adverse health consequences, such as pelvic inflammatory 6 
disease, ectopic pregnancy and infertility, which have an impact on National Health Service 7 
(NHS) costs and health-related quality of life.3  A National Chlamydia Screening Programme 8 
(NCSP) was therefore rolled out in England for 16-24 year olds between 2003 and 2008.4  9 
However, despite recent evidence of a reduction in chlamydia prevalence in England for for 10 
2000 to 2015, concurrent with large-scale population testing5, and the fact that 11 
uncomplicated infection is easy to treat with oral antibiotics, uptake of screening for 12 
chlamydia remains low.6  Worryingly, there has also been a decline over the last four years in 13 
the number of local authorities achieving the public health outcomes framework indicator of 14 
2,300 diagnoses per 100,000 population.1  Barriers identified for young people accessing STI 15 
testing and treatment services include tangible service attributes, such as location of service, 16 
and personal or behavioural factors such as the stigma associated with attendance, 17 
embarrassment, fear of being recognised and privacy concerns.7-9  18 
 19 
A range of options are currently available for young people to access asymptomatic chlamydia 20 
testing and treatment services. For testing, options include attending a genito-urinary 21 
medicine (GUM) clinic, testing via primary care, e.g. pharmacies/general practitioners (GPs), 22 
or via internet testing services where a number of websites offer free self-sampling kits online 23 
with samples sent to laboratories for analysis and results communicated directly to patients.  24 
For individuals who screen positive, options for accessing antibiotic treatment include 25 
attending a GUM/sexual health clinic, GP practice or pharmacy. Even though a national 26 
screening programme exists in England, large geographical variations exist in testing 27 
coverage, from 16% of young people tested for chlamydia in the West Midlands region to 27% 28 
in London, and in the proportion of positive cases treated.1 10  29 
 30 
For many health services, digital technology is now widely regarded by policy makers as one 31 
approach to improve access and reduce costs.11  For chlamydia testing and treatment, a range 32 
of digital options are available, and more technologies are likely to enter the market within 33 
the next 3-5 years.12  These include point-of-care tests13, online postal self-sampling, eSexual 34 
health clinics14, apps and non-face-to-face consultation methods15 16, and self-tests 35 
networked through mobile phones17.  Such innovations provide an opportunity to redesign 36 
current chlamydia screening services with the aim of improving testing and treatment uptake. 37 
However, such service redesign should be based on a sound understanding of the preferences 38 
of young people as service-users for specific attributes of such services. 39 
 40 
Research specifically measuring young people’s preferences nationally for chlamydia testing 41 
and treatment service options is lacking. Even for STI testing services generally, relatively few 42 
studies have used a discrete choice experiment (DCE) design to assess preferences in the UK 43 
population.18-21  In comparison with other preference elicitation methods, a DCE can quantify 44 
the relative importance of different attributes that characterise a new or existing product 45 
and/or service, identifying which attributes people prioritise and which they may be willing 46 
to trade with the view to maximising their utility.22  A DCE requires respondents to choose 47 
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between competing scenarios, e.g. service options, described in terms of a particular attribute 48 
(e.g. time to test result) and a range of levels (e.g. 30min to 14 days) and to compare these 49 
against an alternative scenario.  DCE studies are very useful because they allow a direct 50 
assessment of relative preferences for various existing and hypothetical new service 51 
configurations or treatment approaches.23 52 
 53 
The aim of the present study was to undertake a comprehensive assessment of the 54 
preferences of young people, targeted by the National Chlamydia Screening Programme, for 55 
emerging technology options for testing and treatment in the context of a “check-up test” 56 
where remote care could be medically appropriate.14 To our knowledge, no previous study 57 
has attempted to disentangle strength of preference for attributes associated with new and 58 
emerging options for chlamydia screening (such as self-testing) or treatment (such as online 59 
prescription). Because STI services are “open access” and not subject to gatekeeping by 60 
referral from a clinician, the impact of such disruptive innovations will be directly dependent 61 
on population preferences. Early insight into attributes that could influence whether 62 
individuals are more likely to use a new testing or treatment pathway should therefore be 63 
helpful in informing product development and pathway redesign for future chlamydia 64 
screening service models.24 25 65 
 66 
 67 
METHODS: 68 
 69 
This study was conducted using an exploratory sequential mixed methods design, adopting 70 
recommended stages for undertaking a DCE26, as shown in Figure 1. In selecting methods to 71 
design the questionnaire and conduct the DCE, reference was made to the International 72 
Society for Pharmacoeconomics and Outcomes Research good practice checklist for conjoint 73 
analysis.27 74 
 75 
Patient and public involvement: Young people (with and without experience of STI services) 76 
participated in focus groups to inform priorities included in the DCE; in cognitive testing to 77 
finalise questionnaire design; and in questionnaire completion to identify preferences, as 78 
described in the Acknowledgements. 79 
 80 
Selection of Attributes and Levels 81 
The attributes and associated levels were determined using a four-stage approach.28 More 82 
detailed information is provided in Supplementary Information File 1. 83 
 84 
Literature Reviews 85 
Two literature reviews were undertaken to produce a comprehensive list of potential themes 86 
and factors that might influence young people’s choices. These included: (i) a systematic 87 
review of the use of stated preference studies for STI testing and treatment (PROSPERO Reg: 88 
CRD42014014862); and (ii) a scoping review of other research exploring preferences and 89 
acceptability of STI testing and treatment services. 90 
 91 
Focus Groups 92 
Focus groups were run with young people aged 16-24 years (4 groups, 3-7 per group; total 93 
n=21) to identify which themes and factors young people consider important when choosing 94 
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to test for STIs. Convenience sampling was used to identify participants. Focus group topic 95 
guides incorporated typical vignettes of situations individuals might encounter. Sessions were 96 
recorded, transcribed and thematic analysis was performed to produce a list of potential 97 
attributes and levels.29 98 
 99 
Expert Groups 100 
Four expert groups were convened (n=13), including a range of professionals with expert 101 
knowledge of the service and technology context. Expert groups were asked to review the 102 
focus group findings in terms of clinical feasibility and practicality.26  103 
 104 
Narrative Synthesis 105 
Narrative synthesis30 enabled outputs from the three prior stages to be synthesised for each 106 
potential attribute. This approach was adopted as it offered a clear approach to synthesis 107 
based on the following stages: (i) identification of a checklist of properties against which 108 
attributes can be considered; (ii) tabulation against the checklist; and (iii) conceptual mapping 109 
and triangulation against the checklist. The final synthesis highlighted a tension between 110 
young people’s desire to be tested for a wide range of STIs irrespective of risk, versus clinical 111 
guidelines for selective testing of STIs based on population group prevalence and risk. The 112 
range of STIs presented in the DCE was consequently limited to Chlamydia. Because focus 113 
group findings indicated difficulty in understanding several dimensions of test performance, 114 
test accuracy was expressed in terms of the likelihood of a false negative result. 115 
 116 
Questionnaire Design and Piloting 117 
A generic pairwise choice with opt out question was selected for the questionnaire design. 118 
Respondents were presented with a series of choice sets for which there were 3 responses: 119 
‘option A’, ‘option B’ or ‘I would not test’. A sample choice set is illustrated in Figure 2. The 120 
questionnaire adopted a main effects design using full profiles (all attributes included in the 121 
study). Whilst some DCEs do include an attribute on economic costs, DCEs exploring 122 
preferences for STI testing services in England have generally excluded cost since the NHS 123 
provides treatment ‘free at the point of delivery’20 21  A cost attribute was therefore not 124 
included.  125 
 126 
The questionnaire was developed using SAS 9.4 software to ensure that the design was D-127 
efficient.27  A full factorial design was ruled out in favour of a fractional factorial design 128 
because a full factorial design would have contained 3,072 possible alternatives, which would 129 
have been unmanageable in practice for individuals to complete or for a blocked 130 
questionnaire format to handle31. The smallest 100% efficient design that could be created 131 
included 48 choice sets. These were blocked (halved) into two questionnaires each with 24 132 
choice sets using SAS JMP Pro 9.2.0. Choice set 1 was repeated as choice set 25 in each 133 
questionnaire to provide an internal validity check.  134 
 135 
Three rounds of cognitive testing (n=9) were undertaken to check respondents’ 136 
comprehension of information when making choices. Cognitive testing, undertaken based on 137 
two questionnaires of 24 sets, confirmed that a study based on two such questionnaires was 138 
acceptable to participants.  Some modifications were made to levels where reasons for choice 139 
selection demonstrated that one level (e.g. 8 in 100 false negative) dominated the reason for 140 
selection. Cognitive testing also identified that implausible combinations (e.g. a postal test 141 
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providing a result in two hours) impacted on completion of the task, whilst unlikely (but 142 
feasible) combinations did not. Only implausible combinations were therefore excluded from 143 
the choice sets. The D-Efficiency of the design27 calculated by SAS JMP Pro 9.2.0, prior to the 144 
removal of implausible combinations, was 98.06. The final combination selected for the 145 
questionnaire was the one which created no duplicate choices and which provided an equal 146 
balance of the number of choice sets containing overlap between questionnaires.  147 
 148 
Respondents were asked to provide socio-demographic information, including their age, 149 
gender, ethnicity, region of residence, sexual preference, relationship status and whether 150 
they had previously been tested for an STI. An introduction to the DCE questionnaire provided 151 
background information and an explanation of the attributes and levels. The introduction was 152 
included in the cognitive testing rounds to check comprehension within the target age range. 153 
As a result, the text was modified and diagrams added to illustrate the chlamydia testing 154 
pathways. The final phase of testing demonstrated that the number of choice sets was 155 
acceptable to respondents. The use of an online panel also provided completion time data to 156 
support the internal validity checks, and enabled an accurate record of time taken to 157 
complete the survey. 158 
 159 
Final Attributes and Levels Selected 160 
The six attributes and 24 levels selected for inclusion in the final DCE questionnaire are shown 161 
in table 1. More detailed information used to explain these attributes and levels is provided 162 
in Supplementary Information File 2 (pages 3-7). 163 
 164 
Participants and Recruitment Procedure 165 
Participants were drawn from the general population rather than from health care settings, 166 
thereby providing access to young people aged 16-24 years who had not previously been 167 
tested for an STI. An online national panel (YouthSight)32 was used to maximise geographical 168 
reach and generalisability. Ex-ante sub-group analysis was planned by three age bands (16-169 
18, 19-21, 22-24) and by gender (male, female). Where sub-group analysis is planned, it is 170 
recommended that there should be a minimum of 200 respondents in each sub-group, so a 171 
sample size of 1,200 was required in our study, 600 per questionnaire.33  Consent was 172 
obtained online prior to questionnaire completion. Participants were offered a small 173 
reimbursement of one point (equivalent to £1) for completion of a survey of up to 20 minutes 174 
in length. Points could be exchanged for shopping vouchers.  175 
 176 
Statistical Analyses 177 
The multinomial logit (MNL) model developed by McFadden was used for analysing 178 
responses; this is recognised as the convention for three-response choice set studies (‘option 179 
A’, ‘option B’ or ‘I would not test’).26 34  Analysis utilised STATA13 SE with the method and 180 
code outlined by Ryan et al23  Analyses presented odds ratios (ORs), 95% confidence interval 181 
(CIs) and coefficients for each attribute level. Variables within the model were all treated as 182 
categorical variables for the analysis. Attribute levels were specified using dummy coding, the 183 
preferred form of coding where ORs are to be calculated. Within the model, the levels that 184 
were dropped to form the reference levels reflected those aligned to a ‘typical’ sexual health 185 
clinic pathway (summarised in table 2). To test the internal validity of questionnaire 186 
responses, analyses compared full results against: (i) removal of responses where participants 187 
did not answer the repeated choice set consistently; (ii) removal of any respondents who took 188 
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less than the minimum time (five minutes) observed in cognitive testing to complete the 189 
questionnaire; and (iii) removal of responses containing the opt out question data. Further 190 
tests for internal consistency and rationality were not included, since excluding responses on 191 
this basis may be viewed as an inappropriate imposition of rationality.35  192 
 193 
Demographic characteristics (gender, age and ethnicity) of respondents were compared with 194 
national Census data.36  The influence of patient level characteristics (age, sex and STI testing 195 
history (yes/no)) on the likelihood of not choosing to test was examined. In addition to ex-196 
ante planned sub-group analyses, if sufficient responses were received analysis was also 197 
planned to compare: (i) respondents who had, or had not, previously tested for an STI, and 198 
(ii) those who indicated their relationship status as ‘single’ versus those in a sexual 199 
relationship with one person.  200 
 201 
Trade-off between accuracy and time to result was examined by considering the probability 202 
of uptake for tests with characteristics at the opposite ends of the spectrum i.e. ‘lower 203 
accuracy (5% false negatives), faster time to result (30 min)’ and ‘higher accuracy (2% false 204 
negatives), longer time to result (14 days)’. 205 
 206 
RESULTS: 207 
In total, 1,230 fully completed questionnaires were received, the platform analytics showed 208 
that 460 people had opened the questionnaire but did not complete it, providing a 209 
completion rate of 73%. No further information was available on the demographics of the 210 
460 non-responders nor any information on the point at which they chose to exit the survey, 211 
so these people could not be included in our analyses. Time to complete the 25 choice sets 212 
ranged from one minute 19 seconds to 30 minutes 19 seconds with a median time to 213 
completion of seven minutes 51 seconds. Demographic characteristics of respondents are 214 
summarised in the Supplementary Information File 3 (Part 1). Comparing the DCE sample to 215 
the characteristics of 16-24 year olds in England indicates that gender, age and ethnicity are 216 
broadly in line with national population demographics, with a slight under-representation of 217 
the 16-18 year age group. In terms of the geographical residence of participants, the sample 218 
was broadly in line with the geographical distribution of 16-24 year olds identified in the ONS 219 
Mid-Year Population Estimates 201537, with the exception of a lower proportion of 220 
respondents from the East of England. 221 
 222 
Internal validity checks showed that, in comparison to the full dataset, all checks yielded very 223 
similar ORs with no change in the order of the strength of preference for a level within each 224 
attribute. Results of the internal validity checks are included in the Supplementary 225 
Information File 3 (Part 2). 226 
 227 
OR values for the full dataset and subgroups analysed are presented in table 3 with reference 228 
levels (1.00). Analysis of the trade-off between accuracy and time to result is presented in 229 
table 4. More detailed DCE results, including 95% CIs as well as OR values plus coefficients for 230 
each attribute level for all sub-group analysis are presented in Supplementary Information 231 
File 3 (Part 3).  232 
 233 
In table 3, looking across all attributes and levels for the whole population, participants 234 
expressed the strongest preference for attribute 1 - accuracy of test result (OR 3.242, 95% CI 235 
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3.130–3.359). There are also differences in the strength of preference between males and 236 
females for this attribute (OR 2.951, 95% CI 2.807–3.101 and 3.570, 95% CI 3.396–3.753, 237 
respectively), and between those who had previously tested or not tested (OR 3.000, 95% CI 238 
2.820–3.191 and 3.482, 95% CI 3.331–3.640, respectively). Time to result was the attribute 239 
showing the next strongest preference across all subgroups (OR 1.806, 95% CI 1.711–1.906). 240 
These results are consistent with the logical expectation that people will prefer higher 241 
accuracy and a shorter waiting time. Looking specifically at the trade-off between accuracy 242 
and time to result, table 4 indicates that participants are willing to wait noticeably longer in 243 
order to have a test result with a lower chance of a false negative result.  244 
 245 
When considering how to test, all subgroups demonstrated a preference for self-testing (OR 246 
1.618, 95% CI 1.514–1.729) over attendance at a sexual health clinic. Testing via an outreach 247 
service in an educational/ work setting was found to be the least preferred option (OR 0.821, 248 
95% CI 0.773–0.872). Respondents showed a consistent strength of preference for those 249 
options that do not involve direct contact with healthcare professionals (self-testing and 250 
postal self-sampling), compared with those that do. For consultation and treatment following 251 
a positive test result, there was a preference for non-sexual health clinic pathways with online 252 
consultation to access treatment (OR 1.212, 95% CI 1.150–1.277), treatment via general 253 
practice (OR 1.183, 95% CI 1.123–1.246) and treatment via pharmacy (OR 1.158, 95% CI 254 
1.100–1.220) preferred in the full dataset. At subgroup level (age, gender, previous testing 255 
history and relationship status), more variation was found in the preference order for this 256 
attribute, with the exception of the sexual health clinic which was consistently the least 257 
preferred option across all subgroups (see table 3 and Supplementary Information File 3, Part 258 
3). Finally, the full dataset shows that, if someone wants to access a healthcare professional, 259 
there was no statistically significant preference for instant messenger or email access 260 
compared with accessing the professional face-to-face. Telephone access to a healthcare 261 
professional was the least preferred access option (OR 0.949, 95% CI 0.903–0.998), and the 262 
only statistically significant result when compared with face-to-face access (the reference 263 
level). There was, similarly, no statistically significant difference in preferences for how young 264 
people might access antibiotics apart from a slight preference for the pharmacy versus sexual 265 
health clinic (OR 1.075, 95% CI 1.018–1.134). 266 
 267 
 268 
DISCUSSION:  269 
Our findings indicate that, based on the levels included in the DCE questionnaire, young 270 
people are willing to wait in order to have a chlamydia screening test result with a lower 271 
chance of a false negative result. The conclusion for new test developers is that time to result 272 
is less important than accuracy, and that test users are unlikely to prefer a point-of-care or 273 
self-screening test with lower accuracy than the tests currently available to them. There was 274 
a strong preference for remote access to testing, consultation, and antibiotic prescriptions, 275 
although for accessing a health professional there was no preference between online and 276 
face-to-face methods. This suggests a remote online pathway is acceptable to young people, 277 
as long as test performance remains equivalent.  278 
 279 
In the various hypothetical situations presented, respondents showed a preference for 280 
chlamydia self-testing, self-sampling and postal testing over attendance at a testing location. 281 
For accessing treatment, a general preference was exhibited for online versus traditional GP 282 
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or pharmacy services over clinic services.  For receipt of antibiotics, there was little difference 283 
in preferences. We were also able to identify which attributes people may be willing to trade 284 
to maximise their utility. Looking at the trade-off between accuracy and time to result, we 285 
found that young people are willing to wait noticeably longer in order to have a test result 286 
with a lower chance of a false negative result, reinforcing the need for test equivalence. 287 
 288 
The strengths of this DCE study include, firstly, the robust methods employed to select 289 
attributes and levels, which aligned with the recommendations of Coast et al, ensuring 290 
attributes are “manipulable in policy”.38  Secondly, the fact that participants were drawn from 291 
the general population targeted by the National Chlamydia Screening Programme, rather 292 
than from healthcare settings. This enabled us to access a demographically and geographically 293 
representative national sample of young people, including those who have had no previous 294 
contact with STI services. Finally, the use of an online panel enabled large scale data to be 295 
collected at a reasonable cost and allowed validity checks that would not otherwise have been 296 
possible with postal questionnaire responses. The large sample size also allows comparison 297 
between several subgroups to explore differences based on age, gender, previous testing 298 
history and relationship category.  299 
 300 
However, the study does have a few limitations. The first relates to the selection of attributes 301 
and levels. Whilst the selection process employed was very rigorous, this cannot detract from 302 
the fact that further attributes were identified which might impact on individuals’ choices. To 303 
mitigate against this, where such an attribute was excluded, information was provided in the 304 
survey background section to minimise respondents forming their own views on the impact 305 
of this attribute on the pathway.  306 
 307 
Use of an online panel also provided accurate records of the time taken to complete the 308 
survey, and permitted additional validity checks which would not otherwise have been 309 
possible with a written questionnaire. On the other hand, use of an online panel did exclude 310 
populations who do not have access to the internet, thereby potentially over-representing 311 
the acceptability of online care. However, given the extremely high proportion (97%) of 15-312 
24 year-olds accessing the internet daily via a mobile device39 and owning a smartphone40, it 313 
is evident that the vast majority of the target population could access online care pathways if 314 
they choose to do so. The question of whether these young people have the degree of digital 315 
and health literacy needed for online testing and treatment was not explored in this study.   316 
 317 
Behavioural factors, such as embarrassment7, stigma41 and privacy and anonymity concerns42 318 
43 are known to influence uptake of sexual health services, as well as structural factors such 319 
as convenience and perceived barriers to access8; many of these may be lower for a non-face-320 
to-face service. Balanced against this, access to online testing and treatment is valued less 321 
strongly than attributes such as test accuracy and time to result.  In individual cases a young 322 
person’s preference for remote versus face-to-face testing and treatment might differ.   323 
 324 
Finally, it is difficult to compare the present results to other published DCEs because of key 325 
differences in perspective. Miners et al (sample n=3,358)20 and Llewellyn et al (sample 326 
n=233)21 both only focussed on preferences within existing traditional service delivery 327 
models, and did not incorporate any hypothetical future scenarios (e.g. point-of-care testing, 328 
self-testing or treatment via eHealth/mHealth solutions). Two other DCE studies, which did 329 
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consider self-sampling at home for chlamydia screening18 19, with sample sizes 174 and 126 330 
respectively, both described sending the sample to a laboratory for analysis rather than a self-331 
test. One of these studies19 did identify a stronger preference for attendance at a family 332 
planning clinic, rather than self-sampling, but since participants were recruited from the 333 
waiting room of such a clinic they cannot be considered representative of the general 334 
population targeted by the NCSP. A fifth study, which examined preferences for point-of-care 335 
testing, only surveyed clinicians undertaking STI testing (sample n=218), thus excluding the 336 
population actually targeted for chlamydia screening.44  The only stated preference study that 337 
has considered patients’ preferences for STI self-testing focussed on HIV (sample n=365).45  338 
The authors reported results in line with our findings, with respondents exhibiting a 339 
preference for tests which are accurate, timely and private/ anonymous. However, this study 340 
was undertaken in 2002 prior to smartphones and at a time when self-testing for HIV was still 341 
under development. Importantly for screening tests, only one DCE study to date21 has sought 342 
to include non-service users (i.e. populations with no experience of STI testing). The authors 343 
identified a preference for testing for all STIs, in settings with healthcare professionals with 344 
specialist knowledge present, and for receipt of negative as well as positive results. This study 345 
used a convenience sample of 233 students from two universities which was unlikely to be 346 
geographically or socio-economically representative. All other studies have drawn their DCE 347 
samples from people who were either current service users, or attendees for other, linked 348 
services. Use of such samples represents a significant short-coming when considering the 349 
introduction of new technologies for asymptomatic chlamydia testing and management. 350 
Most sample sizes were also smaller than in the present study. 351 
 352 
A number of questions remain which our research does not address. Firstly, recognising that 353 
the range of STIs included is an important consideration for young people in choosing to test20 354 
21, further research is required to understand this better in the context of potential new 355 
screening pathways which incorporate other STIs (e.g. gonorrhoea). Secondly, our study 356 
highlights a number of methodological considerations where there is an absence of consensus 357 
that may warrant further exploration to improve consistency. These include the number of 358 
choice sets to include in a DCE and the use of repeated choice sets as an internal validity 359 
measure. Finally, given that cost was not included as an attribute in this study, it is not 360 
possible to provide an indication of willingness to pay, or the monetary benefits of potential 361 
service changes, from this DCE.46 362 
 363 
The present study is, to our knowledge, the first to present a large scale, quantitative analysis 364 
of young people’s preferences for attributes of potential new pathways to deliver testing and 365 
treatment of asymptomatic chlamydia, based on a nationally representative population. The 366 
DCE methodology applied also produced a measure of the relative strength of preference 367 
between different attributes and levels, and potential trade-offs. This can provide useful 368 
evidence to technology developers, policy makers, commissioners and service providers. In 369 
particular, it provides a first insight into preferences for the type of technologies currently 370 
under development, and those which might be available for use in the near future, compared 371 
to the features of existing products and services. This can indicate how young people may 372 
respond to changes in pathways and to the introduction of new technologies. 373 
 374 
Within the context of current UK sexual health policy and commissioning of sexual health 375 
services12, this DCE provides supportive evidence for the policy direction of remote chlamydia 376 
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testing and treatment. However, whilst young people overall expressed a stronger preference 377 
for attributes such as self-test, online consultation etc, a small proportion still preferred 378 
existing pathways. This suggests that, in order to maximise benefit, face-to-face services 379 
should continue to be available in addition to any online screening and treatment service. 380 
This will ensure that services are inclusive and accessible irrespective of digital/ health 381 
literacy, while recognising that people’s needs and preferences may change depending on 382 
their personal circumstances.  383 
 384 
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FIGURE LEGENDS 
 
Figure 1 – Stages in Conducting a Discrete Choice Experiment 
 
Figure 2 – Sample Choice Set from the Discrete Choice Experiment 
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Table 1 – Summary of Attributes and Levels Included in the Study 
Full descriptions provided in Supplementary Information File 2 (pages 3-7). 
 
Attribute 
Level 
A1. How you Test A2. Time to Result A3. Accuracy A4. Consultation  
     Method 
A5. Access to HCP A6. How you get  
     Antibiotics 
L1. Self-test 30 mins 2 in 100 (False 
Negative) 
Online Consultation Phone Post to Home 
L2. Self-Sample & Post 2 Hours 5 in 100 (False 
Negative) 
Pharmacy IM Post to Collection 
Point 
L3. Self- Sample & 
Pharmacy 
7 Days  GP Email  Collect from 
Pharmacy 
L4. Self-Sample & 
Education/ Work 
14 Days  Sexual Health Clinic Face to Face Collect from Sexual 
Health Clinic 
L5. GP Practice – 
Sample taken by 
healthcare 
professional 
     
L6. Sexual Health Clinic 
– Sample taken by 
healthcare 
professional 
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Table 2 – Dummy Coding Reference Level 
 
Attribute Reference Level 
How you test Sexual Health Clinic 
Time to result 7 Days 
Accuracy 5 in 100 (False Negative) 
Consultation method Sexual Health Clinic 
Access to HCP Face to Face 
How you get antibiotics Collect from Sexual Health Clinic 
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Table 3 – Overview Odds Ratios for all Sub-Groups Included within the Analysis.  
For further information regarding the explanation of attributes and levels to young people in the questionnaire please see Supplementary File 2. 
Odds Ratio values not statistically significant are shaded blue. 
95% Confidence Intervals provided in Supplementary File 3. 
 
  
Full 
Dataset 
Male Female 16-18 19-21 22-24 Single 
One 
Partner 
Prev Test 
No Prev 
Test 
Attribute & Levels 1,230 607 623 415 406 409 615 512 393 790 
  Odds Ratio 
Odds 
Ratio 
Odds 
Ratio 
Odds 
Ratio 
Odds 
Ratio 
Odds 
Ratio 
Odds 
Ratio 
Odds Ratio 
Odds 
Ratio 
Odds Ratio 
1. How you Test                     
Self-Test 1.618 1.549 1.693 1.664 1.346 1.895 1.632 1.712 1.524 1.678 
Self-Sample and post to a laboratory for analysis 1.358 1.308 1.411 1.477 1.138 1.487 1.380 1.380 1.178 1.465 
Self-Sample and take to a pharmacy for analysis  1.155 1.131 1.180 1.270 1.021 1.185 1.220 1.109 0.945 1.277 
Self-Sample and take to place of education/work for analysis 0.821 0.919 0.733 0.804 0.806 0.852 0.851 0.778 0.761 0.861 
GP Practice – sample taken by a healthcare professional 1.019 1.049 0.990 1.085 1.035 0.941 0.994 1.066 0.885 1.101 
Sexual Health Clinic – sample taken by a healthcare 
professional 
1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
2. Time to Result                     
30 Mins 1.806 1.828 1.786 1.763 1.888 1.772 1.730 1.896 1.808 1.797 
2 Hours 1.402 1.365 1.442 1.326 1.548 1.344 1.311 1.516 1.357 1.423 
7 Days 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
14 Days 0.862 0.844 0.881 0.878 0.882 0.828 0.862 0.862 0.882 0.856 
3. Accuracy                     
2 in 100 False Negative 3.242 2.951 3.570 3.307 3.161 3.282 3.275 3.305 3.000 3.482 
5 in 100 False Negative 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
4. Consultation Method                   
Online Consultation  1.212 1.187 1.239 1.187 1.200 1.253 1.156 1.285 1.174 1.228 
Pharmacy Consultation 1.158 1.106 1.215 1.167 1.209 1.102 1.115 1.225 1.098 1.183 
GP Consultation 1.183 1.172 1.194 1.279 1.142 1.133 1.162 1.189 1.112 1.215 
Sexual Health Clinic Consultation 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
5. Access to Healthcare Professional                   
Phone 0.949 0.937 0.962 1.001 0.902 0.946 0.942 0.926 0.947 0.953 
Instant Messenger 1.027 0.994 1.062 1.108 0.977 1.001 1.025 0.991 1.045 1.025 
Email 1.048 1.034 1.062 1.078 1.038 1.030 1.069 1.001 1.049 1.054 
Face to Face 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
6. How you get Antibiotics                   
Post to Home 1.011 0.996 1.028 0.977 1.010 1.048 0.957 1.055 1.011 1.020 
Post to Collection Point 1.031 1.082 0.983 1.010 1.036 1.047 0.968 1.072 1.034 1.035 
Collect from Pharmacy 1.075 1.064 1.087 1.039 1.106 1.080 1.070 1.056 1.086 1.078 
Collect from Sexual Health Clinic 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
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Table 4 – Trade-off between Accuracy and Time (Probability of Uptake) 
 
  Full Dataset Male Female 16-18 19-21 22-24 Single One Partner Prev Test No Prev Test 
Pathways:  
(n in 1001 / time2)                     
5 in 1001/ 30min2 38% 40% 35% 36% 39% 38% 36% 39% 40% 36% 
2 in 100/ 14 days 58% 55% 62% 59% 58% 59% 59% 58% 58% 59% 
Not Test 4% 5% 3% 5% 3% 3% 4% 3% 2% 5% 
Total 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 
 
1 Test accuracy = n in 100 people will be told they don’t have chlamydia when they do 
2 Time to receipt of result 
 
 
